Ergoteles’s Rubius Therapeutics, Inc RUBY Stock Holding History

Ergoteles’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-57,747	Closed	-$9.94K	–	1983
2022 Q4	$9.94K	Buy	+57,747	New	+$15.8K	﹤0.01%	1372
2022 Q3	–	Sell	-213,613	Closed	-$182K	–	2174
2022 Q2	$182K	Buy	+213,613	New	+$359K	0.01%	1364
2022 Q1	–	Sell	-30,314	Closed	-$293K	–	1748
2021 Q4	$293K	Buy	+30,314	New	+$420K	0.01%	864
2020 Q4	–	Sell	-13,407	Closed	-$67K	–	971
2020 Q3	$67K	Buy	+13,407	New	+$71K	0.01%	547

Other funds holding RUBY

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

CGL

Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Ergoteles's RUBY Position: Q1 2023 in Review

Ergoteles sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 57,747 shares — an estimated $9.94K sold.

Ergoteles first reported a position in RUBY in Q3 2020 and held it in 4 quarters. The position peaked at $293K in Q4 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

Ergoteles reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 57,747 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $9.94K.
Ergoteles first reported a position in Rubius Therapeutics, Inc in Q3 2020 and held it in 4 quarters.
Ergoteles's Rubius Therapeutics, Inc position peaked at $293K in Q4 2021.
7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.